Hookipa Pharma Net Worth
Hookipa Pharma Net Worth Breakdown | HOOK |
Hookipa Pharma Net Worth Analysis
Hookipa Pharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Hookipa Pharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Hookipa Pharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Hookipa Pharma's net worth analysis. One common approach is to calculate Hookipa Pharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Hookipa Pharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Hookipa Pharma's net worth. This approach calculates the present value of Hookipa Pharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Hookipa Pharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Hookipa Pharma's net worth. This involves comparing Hookipa Pharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Hookipa Pharma's net worth relative to its peers.
Enterprise Value |
|
To determine if Hookipa Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Hookipa Pharma's net worth research are outlined below:
| Hookipa Pharma generated a negative expected return over the last 90 days | |
| Hookipa Pharma has high historical volatility and very poor performance | |
| Hookipa Pharma may become a speculative penny stock | |
| The company reported the previous year's revenue of 43.95 M. Net Loss for the year was (43.5 M) with loss before overhead, payroll, taxes, and interest of (23.19 M). | |
| Hookipa Pharma currently holds about 117.92 M in cash with (76.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.16, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Hookipa Pharma has a frail financial position based on the latest SEC disclosures | |
| Roughly 59.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Hooked Protocol Price Up 7.7 percent Over Last 7 Days |
Hookipa Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Hookipa Pharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Hookipa Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Hookipa Pharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Hookipa Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Hookipa Pharma backward and forwards among themselves. Hookipa Pharma's institutional investor refers to the entity that pools money to purchase Hookipa Pharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Citadel Advisors Llc | 2024-12-31 | 32.7 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 25.3 K | Engineers Gate Manager Lp | 2024-12-31 | 23.7 K | Royal Bank Of Canada | 2024-12-31 | 19.4 K | State Street Corp | 2024-12-31 | 17 K | Northern Trust Corp | 2024-12-31 | 15.7 K | Millennium Management Llc | 2024-12-31 | 15.3 K | Blackrock Inc | 2024-12-31 | 12.2 K | Boothbay Fund Management, Llc | 2024-12-31 | 11.7 K | Baker Bros Advisors Lp | 2024-12-31 | 812.8 K | Siren, L.l.c. | 2024-12-31 | 566.6 K |
Follow Hookipa Pharma's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 15.07 M.Market Cap |
|
Project Hookipa Pharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.53) | (0.55) | |
| Return On Capital Employed | (0.89) | (0.93) | |
| Return On Assets | (0.53) | (0.55) | |
| Return On Equity | (0.85) | (0.89) |
When accessing Hookipa Pharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Hookipa Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Hookipa Pharma's profitability and make more informed investment decisions.
Evaluate Hookipa Pharma's management efficiency
Hookipa Pharma has return on total asset (ROA) of (0.2296) % which means that it has lost $0.2296 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6168) %, meaning that it created substantial loss on money invested by shareholders. Hookipa Pharma's management efficiency ratios could be used to measure how well Hookipa Pharma manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.55. The value of Return On Capital Employed is expected to slide to -0.93. At this time, Hookipa Pharma's Total Current Liabilities is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 139.4 M this year, although the value of Non Current Liabilities Total will most likely fall to about 6.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 4.08 | 3.88 | |
| Tangible Book Value Per Share | 4.08 | 3.88 | |
| Enterprise Value Over EBITDA | 0.26 | 0.28 | |
| Price Book Value Ratio | 0.49 | 0.64 | |
| Enterprise Value Multiple | 0.26 | 0.28 | |
| Price Fair Value | 0.49 | 0.64 | |
| Enterprise Value | -13.6 M | -12.9 M |
The management team at Hookipa Pharma has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Enterprise Value Revenue 1.9077 | Revenue | Quarterly Revenue Growth (0.82) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Hookipa Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Hookipa Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Hookipa Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hookipa Pharma time-series forecasting models is one of many Hookipa Pharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Hookipa Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Hookipa Pharma Earnings per Share Projection vs Actual
Hookipa Pharma Corporate Management
| Lukas Flatz | CoFounder | Profile | |
| Klaus Orlinger | Chief Officer | Profile | |
| Reinhard Kandera | CFO Director | Profile | |
| Matthew Beck | Executive Relations | Profile | |
| Mark Winderlich | Chief Officer | Profile | |
| Joern Aldag | CEO Director | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hookipa Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Hookipa Stock please use our How to buy in Hookipa Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hookipa Pharma. If investors know Hookipa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hookipa Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.47) | Revenue Per Share | Quarterly Revenue Growth (0.82) | Return On Assets | Return On Equity |
The market value of Hookipa Pharma is measured differently than its book value, which is the value of Hookipa that is recorded on the company's balance sheet. Investors also form their own opinion of Hookipa Pharma's value that differs from its market value or its book value, called intrinsic value, which is Hookipa Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hookipa Pharma's market value can be influenced by many factors that don't directly affect Hookipa Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hookipa Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Hookipa Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hookipa Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.